Evaxion A/S (NASDAQ:EVAX) vs. EUDA Health (NASDAQ:EUDA) Financial Contrast

Evaxion A/S (NASDAQ:EVAX) and EUDA Health (NASDAQ:EUDA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Volatility and Risk

Evaxion A/S has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, EUDA Health has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.

Profitability

This table compares Evaxion A/S and EUDA Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	-316.03%	-532.72%	-78.32%
EUDA Health	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent recommendations for Evaxion A/S and EUDA Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	0	0	2	0	3.00
EUDA Health	0	0	0	1	4.00

Evaxion A/S currently has a consensus price target of $10.00, suggesting a potential upside of 280.23%. Given Evaxion A/S’s higher possible upside, equities analysts clearly believe Evaxion A/S is more favorable than EUDA Health.

Valuation & Earnings

This table compares Evaxion A/S and EUDA Health”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$3.34 million	1.10	-$10.57 million	($1.16)	-2.27
EUDA Health	$4.01 million	29.19	-$15.36 million	N/A	N/A

Evaxion A/S has higher earnings, but lower revenue than EUDA Health.

Institutional and Insider Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 4.4% of EUDA Health shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

EUDA Health beats Evaxion A/S on 7 of the 13 factors compared between the two stocks.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About EUDA Health

EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.